| abstract |
A product containing: a) an immunosuppressive agent (A) and (b) at least one immunosuppressive 2,2-bi-1H-pyrrole compound (B) having the formula (I) represented below where R1 is hydrogen, phenyl, C1-C20 alkyl or C2-C20 alkenyl, where the alkyl and alkenyl groups are substituted or substituted by 1 to 3 substituents, which are the same or different, which are independently selected from halogen, C1-C6 alkoxy , hydroxy, aryl yaryloxy; R2 is hydrogen, C1-C6 alkyl, cyano, carboxy or (C1-C6 alkoxy) carbonyl; R3 is halogen, hydroxy or C1-C11 alkoxy unsubstituted or substituted by phenyl; R4 is hydrogen, C1-C6 alkyl, or phenyl; each of R5 and R6, which may be the same or different, is, independently, hydrogen, C2-C20 alkanoyl, C3-C20 alkenoyl, phenyl, C1-C20 alkyl or C2-C20 alkenyl; or two of R4, R5, and R6, taken together, form a C4-C12 polymethyl chain, which is unsubstituted or substituted by a C1-C12 alkyl group, a C2-C12 alkenyl group, or a C1- alkyl group. C12; or a pharmaceutically acceptable salt thereof; in the form of a combined preparation for use simultaneously, separately or sequentially in immunosuppression therapy, said preparation possesses enhanced immunosuppressive activity with respect to products containing the immunosuppressive agent (A) or compound 2,2-bi- Immunosuppressive 1H-pyrrole (B). |